Breast Cancer | Specialty

Dr. Anders on Abemaciclib in HR+ Breast Cancer With Brain Metastases

June 22nd 2019

Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discussed the use of abemaciclib, a selective CDK4/6 inhibitor, in patients with hormone receptor–positive, HER2-negative metastatic brain cancer with brain metastases.

Talazoparib Approved in Europe for BRCA-Mutant Breast Cancer

June 21st 2019

The European Commission has approved single-agent talazoparib for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer.

O'Regan Assesses Treatment Courses and Durations in Early-Stage HR+ Breast Cancer

June 21st 2019

Ruth O'Regan, MD, discusses current approaches to treatment escalation and de-escalation, as well as the use of retrospective molecular profiling, which may help address some unanswered questions in the field.

Dr. Rao on Abemaciclib Post-Palbociclib in Metastatic Breast Cancer

June 20th 2019

Ruta Rao, MD, associate professor of medical oncology, Rush University Medical Center, discusses the use of abemaciclib with or without fulvestrant for the treatment of hormone receptor–positive and HER2-negative metastatic breast cancer following prior treatment with palbociclib.

Neratinib Combo Improves PFS in HER2+ Breast Cancer

June 6th 2019

Neratinib combined with capecitabine reduced the risk of disease progression or death by 24% compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who received at least 2 prior lines of HER2-targeted therapy.

Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer

June 5th 2019

Adding the Akt inhibitor capivasertib to fulvestrant led to a more than doubling of progression-free survival compared with fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.

Margetuximab Superior to Trastuzumab on PFS in HER2-Positive Metastatic Breast Cancer Carriers of CD16A-F Allele

June 5th 2019

Margetuximab, a novel Fc-engineered HER2-targeted antibody, improved progression-free survival compared with trastuzumab in patients with pretreated HER2-positive metastatic breast cancer in the open-label phase III SOPHIA clinical trial.

High TMB Metastatic Breast Cancer Responds to Pembrolizumab Monotherapy

June 2nd 2019

Examination of a cohort of patients with metastatic breast cancer and high mutational burden who were enrolled in the phase II Targeted Agent and Profiling Utilization Registry basket study shows that pembrolizumab monotherapy has antitumor activity in this population of heavily pretreated patients.

ASCO 2019: Dr. Plimack Highlights Practice-Changing Data for Genitourinary Cancers

June 2nd 2019

ASCO 2019: Dr. Ferris Discusses the Latest Data in Head and Neck Cancer

June 2nd 2019

Dr. Tolaney Highlights New Breast Cancer Combination Therapies

June 2nd 2019

ASCO 2019: Dr. Monk on Promising Abstracts in Gynecologic Malignancies

June 2nd 2019

ASCO 2019: Dr. Horn Highlights Progress in Lung Cancer

June 2nd 2019

ASCO 2019: Dr. Shah Covers Potentially Practice-Changing GI Cancer Studies

June 2nd 2019

ASCO 2019: Dr. Tagawa Highlights Key Prostate Cancer Data

June 2nd 2019

ASCO 2019: Dr. Rajkumar Highlights Practice-Changing Multiple Myeloma Studies

June 2nd 2019

OncLive News Network On Location: In Chicago Tuesday, June 4

June 2nd 2019

OncLive News Network On Location: In Chicago Monday, June 3

June 2nd 2019

OncLive News Network On Location: In Chicago Sunday, June 2

June 2nd 2019

OncLive News Network On Location: In Chicago Saturday, June 1

June 2nd 2019